A Phase 3 interventional study of CTx-1301 - Dexmethylphenidate 25mg and CTx-1301 - Dexmethylphenidate 37.5mg in ADHD, ADHD - Combined Type and Attention Deficit Hyperactivity Disorder Combined, sponsored by Cingulate Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Cingulate Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 558th largest by enrollment of the 706 interventional ones that give a count, is one of 31 that started in 2022, is one of 121 in phase 3, and was the 678th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–17
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–13
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Alkermes, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
807 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 108 · Phase 3 135 · Phase 4 148
First in 1985; this study’s year is marked. 31 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 70 across the 706 interventional studies, 115 across the 98 observational. Of the 644 that completed or were terminated, 302 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
262 of 807 have an industry lead sponsor. The 10 most frequent:
Cingulate Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Cingulate Therapeutics has 4 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
34 of the studies in Attention Deficit Disorder with Hyperactivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04946253University of PittsburghSKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care | 2026-11 |
| NCT05683756University of PittsburghOptimizing Attention and Sleep Intervention Study | 2026-12 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
Add all 34 to your calendar (.ics) → With an account.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.
A single-center, dose-optimized, double-blind, randomized, placebo-controlled, parallel efficacy and safety laboratory classroom study with CTx-1301 in approximately 25 adults aged 18 to 55 years with ADHD. The study will be comprised of a screening period, a dose-optimization phase, a double-blind randomized phase, and a safety follow-up phase. Subjects will undergo a screening visit prior to entering a 5-week dose-optimization phase. During the dose-optimization phase subjects will have weekly visit and will be titrated to doses ranging between 25mg-50mg of CTx-1301. Eligible subjects will be randomized to their optimal dose or placebo in a 1:1 ratio after completing a practice Adult Laboratory Classroom (ALC) visit with 4 PERMP assessments. Subjects will take their assigned/randomized dose over the following 7-day period. On the 7th day subjects will complete a full ALC visit. The duration of the full ALC visit will be approximately 17 hours. Subjects will have an in-clinic safety follow-up visit within 7 days after the full adult laboratory classroom visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eligibility Criteria:
Subjects will be required to meet the following criteria at the end of the dose-optimization phase in order to be eligible for the double-blind, randomized treatment phase. These criteria are based on the efficacy and safety observed over the 5-week dose-optimization period.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will be titrated to their optimal dose during the dose-optimization phase. The starting dose for all subjects at Day 0 is 25mg. Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
Drug: CTx-1301 - Dexmethylphenidate 25mg
All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg . Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
Drug: CTx-1301 - Dexmethylphenidate 37.5mg
All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg . Each subject is expected to be on their optimal dose for 2 sequential weeks prior to the randomization phase. Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
Drug: CTx-1301 - Dexmethylphenidate 50mg
Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase.
Drug: Placebo
25mg CTx-1301 (Dexmethylphenidate tablet)
Also known as: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg of CTx-1301.
37.5mg CTx-1301 (Dexmethylphenidate tablet)
Also known as: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg of CTx-1301.
50mg CTx-1301 (Dexmethylphenidate tablet)
Also known as: All subjects will be titrated to their optimal dose during the dose-optimization phase. Possible doses are 25mg, 37.5mg, or 50mg of CTx-1301.
Placebo
Also known as: Subjects will be randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomized phase.
The Primary Efficacy Analysis Will Analyze the Change in PERMP Scores From Baseline (Pre-dose) at Visit 8 to Hour 16 at Visit 8.
The Permanent Product Measure of Performance-Correct (PERMP-C) is an objective, validated, skill-adjusted 10-minute math test that measures attention and accuracy in ADHD. Performance is measured by the number of math problems answered correctly. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.
Time frame: Average of the change of the PERMP-C scores from baseline defined as pre-dose score at Visit 8 which was at end of 7-day double-blind period to PERMP-C scores at hour 16 at Visit 8.
Key Secondary Analysis Will Analyze the Change in PERMP Scores From Baseline at Each Time Point During the Laboratory Environment at Visit 8.
The Permanent Product Measure of Performance-Correct (PERMP-C) is an objective, validated, skill-adjusted 10-minute math test that measures attention and accuracy in ADHD. Performance is measured by the number of math problems answered correctly. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.
Time frame: Average of the change of the PERMP-C scores from baseline defined as pre-dose score at Visit 8 which was at end of 7-day double-blind period to PERMP-C scores at hours .5,1,3,6,9,12,13,14,15, and 16.
Key Secondary Analysis Will Analyze the Change From Baseline (Pre-dose at Visit 2) of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.
The Clinical Global Impression-Severity (CGI-S) scale is a 7-point clinician-rated tool that measures the overall severity of a subject's illness. It rates subjects from 1 (normal) to 7 (among the most extremely ill). A higher score means a worse outcome.
Time frame: Baseline (pre-dose at Visit 2) to Visit 8 (approximately 6 weeks).
Safety - Incidence of TEAEs
Treatment Emergent Adverse Events (TEAEs) will be evaluated at each visit
Time frame: Screening (Visit 1) to Visit 9 (approximately 7-11 weeks, depending on screening window)
The Purpose of This Study is to Estimate the Effect Size of Treatment on the PERMP Instrument in an Adult ADHD Population as Defined by the Inclusion/Exclusion Criteria.
The purpose of this study is to estimate the effect size of treatment on the PERMP instrument in an adult ADHD population as defined by the inclusion/exclusion criteria. The Permanent Product Measure of Performance (PERMP) is an objective, validated, skill-adjusted 10-minute math test that measures attention in ADHD. The PERMP correct score comprises the number of math problems answered correctly. A higher PERMP score indicates better performance.Though primary and secondary endpoints are defined in accordance with International Conference on Harmonization (ICH) E9 guidelines, this study is not intended to demonstrate statistical significance via treatment group comparisons.
Time frame: Baseline (pre-dose) at Visit 8 then post-dose at hours .5,1,3,6,9,12,13,14,15, and 16.
A total of 26 subjects were enrolled, of which 21 were randomized to double-blind, placebo controlled treatment at one study center from December 29, 2022 to June 6, 2023.
| Milestone | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Period | Placebo |
|---|---|---|---|
| Started | 26 | 0 | 0 |
| Completed | 21 | 0 | 0 |
| Not completed | 5 | 0 | 0 |
| Milestone | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Period | Placebo |
|---|---|---|---|
| Started | 0 | 11 | 10 |
| Completed | 0 | 11 | 10 |
| Not completed | 0 | 0 | 0 |
The Permanent Product Measure of Performance-Correct (PERMP-C) is an objective, validated, skill-adjusted 10-minute math test that measures attention and accuracy in ADHD. Performance is measured by the number of math problems answered correctly. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.
| score on a scale | CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|
| The Primary Efficacy Analysis Will Analyze the Change in PERMP Scores From Baseline (Pre-dose) at Visit 8 to Hour 16 at Visit 8. | 24.94 (15.474 to 34.415) | 13.09 (3.149 to 23.033) |
The Permanent Product Measure of Performance-Correct (PERMP-C) is an objective, validated, skill-adjusted 10-minute math test that measures attention and accuracy in ADHD. Performance is measured by the number of math problems answered correctly. The minimum possible score is 0. The highest possible score is 400, with higher scores mean higher performance and less severe ADHD symptoms.
| score on a scale | CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|
| Hour .5 | 14.4 (7.02 to 21.78) | 7.2 (-0.59 to 14.91) |
| Hour 1 | 19.2 (11.86 to 26.55) | 10.2 (2.46 to 17.89) |
| Hour 3 | 18.6 (8.27 to 28.97) | 7.2 (-3.65 to 18.08) |
| Hour 6 | 26.8 (18.14 to 33.45) | 11.1 (2.04 to 20.21) |
| Hour 9 | 24.7 (13.71 to 35.63) | 7.9 (-3.64 to 19.36) |
| Hour 12 | 21.4 (9.51 to 33.27) | 14.1 (1.60 to 26.54) |
| Hour 13 | 27.8 (14.33 to 41.33) | 18.7 (4.51 to 32.86) |
| Hour 14 | 32.4 (17.67 to 47.03) | 19.6 (4.20 to 35.03) |
| Hour 15 | 35.3 (20.23 to 50.44) | 16.7 (0.87 to 32.59) |
| Hour 16 | 28.8 (13.31 to 44.37) | 18.3 (1.97 to 34.58) |
The Clinical Global Impression-Severity (CGI-S) scale is a 7-point clinician-rated tool that measures the overall severity of a subject's illness. It rates subjects from 1 (normal) to 7 (among the most extremely ill). A higher score means a worse outcome.
| score on a scale | CTx-1301 (Dexmethylphenidate Tablet) | Placebo |
|---|---|---|
| Key Secondary Analysis Will Analyze the Change From Baseline (Pre-dose at Visit 2) of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8. | -1.1 (-1.40 to -0.79) | -0.1 (-0.42 to 0.23) |
Treatment Emergent Adverse Events (TEAEs) will be evaluated at each visit
| Participants | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Treatment Phase | Placebo Double-Blind Treatment Phase |
|---|---|---|---|
| TEAE | 25 | 1 | 3 |
| TEAE related to study drug | 22 | 1 | 3 |
| Severe TEAE | 5 | 0 | 0 |
| SAE | 0 | 0 | 0 |
| SAE related to study drug | 0 | 0 | 0 |
| AE leading to withdrawal | 3 | 0 | 0 |
| AE leading to death | 0 | 0 | 0 |
The purpose of this study is to estimate the effect size of treatment on the PERMP instrument in an adult ADHD population as defined by the inclusion/exclusion criteria. The Permanent Product Measure of Performance (PERMP) is an objective, validated, skill-adjusted 10-minute math test that measures attention in ADHD. The PERMP correct score comprises the number of math problems answered correctly. A higher PERMP score indicates better performance.Though primary and secondary endpoints are defined in accordance with International Conference on Harmonization (ICH) E9 guidelines, this study is not intended to demonstrate statistical significance via treatment group comparisons.
| units on a scale | Effect Size (CTx-1301 - Placebo) |
|---|---|
| Hour .5 | 1.41 |
| Hour 1 | 1.76 |
| Hour 3 | 1.58 |
| Hour 6 | 2.60 |
| Hour 9 | 2.20 |
| Hour 12 | 0.88 |
| Hour 13 | 0.97 |
| Hour 14 | 1.24 |
| Hour 15 | 1.77 |
| Hour 16 | 0.98 |
Collected over Screening (Visit 1) to Visit 9 (approximately. 7-11 weeks, depending on screening window). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | 0/26 (0%) | 0/26 (0%) | 25/26 (96.2%) |
| CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Treatment Phase | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Placebo | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Treatment Phase | Placebo |
|---|---|---|---|
| Dry MouthGastrointestinal disorders | 15/26 | 0/11 | 0/10 |
| AnxietyPsychiatric disorders | 11/26 | 0/11 | 0/10 |
| InsomniaPsychiatric disorders | 11/26 | 0/11 | 0/10 |
| Decreased AppetiteMetabolism and nutrition disorders | 10/26 | 0/11 | 0/10 |
| HeadacheNervous system disorders | 8/26 | 0/11 | 1/10 |
| IrritabilityPsychiatric disorders | 7/26 | 0/11 | 0/10 |
| NauseaGastrointestinal disorders | 4/26 | 0/11 | 0/10 |
| Feeling JitteryGeneral disorders | 4/26 | 0/11 | 0/10 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/26 | 0/11 | 0/10 |
| Affect LabilityPsychiatric disorders | 3/26 | 0/11 | 0/10 |
All subjects were titrated to their optimal dose during the dose-optimization phase. Each subject was expected to be on their optimal dose for 2 sequential weeks prior to the double-blind randomization phase. Subjects were randomized (1:1) to their optimal dose or placebo in the 7-day, double-blind, randomization phase. As a result, 26 subjects entered the dose optimization phase and 21 completed the dose optimization phase. Twenty one subjects entered and completed the double-blind phase.
| Age, Customized(Participants) | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Period | Placebo | Total |
|---|---|---|---|---|
| 18 to 55 Dose Optimization Phase | 26 | 0 | 0 | 26 |
| 18 to 55 Double-Blind Treatment Phase | 0 | 11 | 10 | 21 |
| Sex: Female, Male(Participants) | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Period | Placebo | Total |
|---|---|---|---|---|
| Dose Optimization Phase — Female | 19 | — | — | 19 |
| Dose Optimization Phase — Male | 7 | — | — | 7 |
| Double-Blind Phase — Female | — | 10 | 7 | 17 |
| Double-Blind Phase — Male | — | 1 | 3 | 4 |
| Ethnicity (NIH/OMB)(Participants) | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Period | Placebo | Total |
|---|---|---|---|---|
| Dose Optimization Phase — Hispanic or Latino | 7 | — | — | 7 |
| Dose Optimization Phase — Not Hispanic or Latino | 19 | — | — | 19 |
| Dose Optimization Phase — Unknown or Not Reported | 0 | — | — | 0 |
| Double-Blind Phase — Hispanic or Latino | — | 4 | 1 | 5 |
| Double-Blind Phase — Not Hispanic or Latino | — | 7 | 9 | 16 |
| Double-Blind Phase — Unknown or Not Reported | — | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Period | Placebo | Total |
|---|---|---|---|---|
| Dose Optimization Phase — American Indian or Alaska Native | 0 | — | — | 0 |
| Dose Optimization Phase — Asian | 3 | — | — | 3 |
| Dose Optimization Phase — Native Hawaiian or Other Pacific Islander | 2 | — | — | 2 |
| Dose Optimization Phase — Black or African American | 1 | — | — | 1 |
| Dose Optimization Phase — White | 20 | — | — | 20 |
| Dose Optimization Phase — More than one race | 0 | — | — | 0 |
| Dose Optimization Phase — Unknown or Not Reported | 0 | — | — | 0 |
| Double-Blind Phase — American Indian or Alaska Native | — | 0 | 0 | 0 |
| Double-Blind Phase — Asian | — | 1 | 2 | 3 |
| Double-Blind Phase — Native Hawaiian or Other Pacific Islander | — | 1 | 1 | 2 |
| Double-Blind Phase — Black or African American | — | 1 | 0 | 1 |
| Double-Blind Phase — White | — | 8 | 7 | 15 |
| Double-Blind Phase — More than one race | — | 0 | 0 | 0 |
| Double-Blind Phase — Unknown or Not Reported | — | 0 | 0 | 0 |
| Region of Enrollment(Participants) | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Period | Placebo | Total |
|---|---|---|---|---|
| United States | 26 | 0 | 0 | 26 |
| Region of Enrollment(Participants) | CTx-1301 (Dexmethylphenidate Tablet) Dose Optimization Phase | CTx-1301 (Dexmethylphenidate Tablet) Double-Blind Period | Placebo | Total |
|---|---|---|---|---|
| United States | 0 | 11 | 10 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2022 to primary completion in Jun 2023, 5 months.
Results were first posted in Jul 2026, 3 years after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 5 months is below that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CTX-1301
Attention Deficit Disorder with Hyperactivity →
Cingulate Therapeutics